Bioxytran reports first CIDP patient on PLICID shows functional gains; no adverse events

BIOXYTRAN, INC

First CIDP patient treated with once-weekly IV PLICID regained finger use and ability to walk miles.
No adverse events reported during treatment; company cites case as supporting further evaluation.
PLICID is an ASI-designed galectin antagonist; Bioxytran plans a larger clinical study.
Company acknowledges single-patient observations are not sufficient to establish safety or efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.